Booster for neutrophil granulocytes - 27/10/2021

Acetate supports immune cells to fight against sepsis

Blood poisoning is the most dangerous complication of bacterial infections and often leads to death. Researchers at the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen have now identified acetate as a potent agent for stimulating innate immune system cells, supporting their ability to destroy bacteria.

An international study with about 3000 patients confirms the validity of a new classification system for meningiomas. It combines tissue characteristics (histology) with molecular analyses and thus improves therapy planning.

Optimised peptides against infections and cancer - 07/10/2021

New bioactive ingredients from the peptidome treasure chest

Peptides are increasingly coming into scientific focus for application in diagnostics and therapy. The human body is full of these protein fragments, but only a fraction have been characterised. So there is enormous potential for discovering new biologically active substances that can help in the fight against bacteria, viruses and cancer. A collaborative research centre at Ulm University Hospital is on the trail of these promising fragments.

Cyber Valley researchers have created medical educational tools that could potentially train the surgeons of the future, much like flight simulators train pilots. The team developed a range of artificial organ phantoms to serve as training platforms for surgeons. Thanks to the structured data of experienced medical professionals, a quantitative and objective assessment of a trainee’s skills can be assessed in real time.

Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have developed antibodies that have two antigen-binding sites and can couple cancer cells with effector cells of the immune system. In laboratory tests, these bridging antibodies, together with an enhancer antibody, were able to specifically mobilize the body's own immune defenses and destroy breast cancer cells.

Christiane Opitz, scientist at the German Cancer Research Center, is being awarded this year's Ita Askonas Prize of the European Federation of Immunological Societies. Opitz has discovered how tumor cells use certain metabolites to protect themselves against the immune system. Her research findings may provide important clues for the development of new therapeutic concepts.

On the one hand, blood vessels supply tumors with nutrients and, on the other, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a distant organ is promoted by factors whose production is induced by the primary tumor itself. Scientists have now identified a new growth factor produced by blood vessels that enables tumor cells to metastatically colonize organs.

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the publication entitled “Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model” in the peer-reviewed Journal of Hepatology.

The risk of colorectal cancer can be predicted more accurately by determining seven blood-based micro-RNAs (miRNAs) than by using traditional methods - and can be done so many years before a diagnosis is made. In a current study, researchers from the German Cancer Research Center and the National Center for Tumor Diseases (NCT) Heidelberg show that miRNA profiles provide greater predictive accuracy than genetic or lifestyle-based risk…

PixelBiotech GmbH - 27/07/2021

Searching for tracks with cytogenetics and AI

The startup Pixelbiotech combines fluorescence techniques with artificial intelligence to detect DNA and RNA in medical samples. HuluFISH is the name of the method, which allows for countless applications - from detecting viral infections, such as COVID-19 or African swine fever virus, to the quality control of gene and immunotherapeutic procedures in cancer medicine.

Scientists from the German Cancer Research Center and Heidelberg University Hospital have for the first time been able to delay the development of hereditary colorectal cancer with a protective vaccination. Mice with a hereditary predisposition to colorectal cancer survived significantly longer after vaccination than unvaccinated animals. Combining the vaccination with an anti-inflammatory drug increased the protective effect.

Gene regulation - 20/07/2021

The many faces of the epigenetic regulator MOF

Epigenetic modifications play a crucial role in coordinated gene transcription, and are required for a fertilised egg cell to be able to develop into an organism with different cell types. Dr. Asifa Akhtar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has been studying the essential epigenetic regulator protein MOF for 20 years.

Under certain conditions, our immune system can efficiently fight off infectious diseases and cancer. T cells, especially the gamma delta T cell type, play an important role in this. The issue is that this cell type is extremely infrequent in the human body. Researchers at the University Hospital Tübingen, the University of Heidelberg and the European Molecular Biology Laboratory (EMBL) have now succeeded in finding the cause for the formation of…

Through a complex, self-reinforcing feedback mechanism, colorectal cancer cells make room for their own expansion by driving surrounding healthy intestinal cells to death - while simultaneously fueling their own growth. This feedback loop is driven by an activator of the innate immune system. Researchers from the German Cancer Research Center (DKFZ) and the University of Heidelberg discovered this mechanism in the intestinal tissue of fruit…

Scientists from the EMBL and the German Cancer Research Center have presented a new method for generating metabolic profiles of individual cells. The method, which combines fluorescence microscopy and a specific form of mass spectroscopy, can analyze over a hundred metabolites and lipids from more than a thousand individual cells per hour. Researchers expect the method to better answer a variety of biomedical questions in the future.

For the first time, scientists from the German Cancer Consortium (DKTK) partner site in Essen/Düsseldorf have discovered stem cells of the hematopoietic system in glioblastomas, the most aggressive form of brain tumor. These hematopoietic stem cells promote division of the cancer cells and at the same time suppress the immune response against the tumor.

Article - 10/06/2021

New study: vaccine therapy for treating patients with chronic leukaemia

Personalised peptide vaccination is expected to improve the treatment of patients with chronic lymphocytic leukaemia. A research team from Tübingen has started a Phase I clinical trial with CLL patients who will undergo ibrutinib treatment. Other leukaemia sufferers as well as cancer patients in general are also expected to benefit in the long term.

Article - 31/05/2021

Tracking down tumour-associated pain in pancreatic cancer

Pancreatic cancer comes along quietly: unnoticed for a long time, it often triggers excruciating pain as the tumour progresses. This pain is associated with cancer cells invading pancreatic nerves. Dr. Michael Hirth from Mannheim University Hospital has shed some light on the complex communication between cancer cells and nerve cells. His findings could eventually be used for personalised pain therapies.

Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.

Vaccine development - 25/05/2021

Vaccines - a beacon of hope in the fight against pandemics

Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology.

Signal mechanisms in inflammatory processes - 18/05/2021

Newly discovered substances activate the inflammasome in macrophages

Low-grade chronic inflammation caused by components of the innate immune system may increase the risk of developing a variety of diseases in the long term. In their search for the signalling mechanisms underlying these inflammatory processes, Prof. Dr. Olaf Groß' research group at the Freiburg University Medical Centre discovered new active substances with immunostimulatory properties that may open up additional possibilities in cancer…

The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells.

Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.

Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.

Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…

A new method allows stem cells and cancer stem cells to be studied at the single cell level and the resulting cell clones to be traced directly. Studying thousands of individual cells in parallel, the researchers combined the analysis of the genomic cancer mutations with the associated expression profiles.

Article - 17/03/2021

Epigenetic switches in bacteria as biosensors

The analysis of pathogen biomarkers and biomarkers for the diagnosis of diseases can be crucial for health. However, the detection of pathogens and diseases depends on a sensitive and reliable method that delivers rapid results. Biosensors have such properties. Researchers at the Institute of Biochemistry and Technical Biochemistry (IBTB) at Stuttgart University have constructed an epigenetic circuit composed of plasmids that might make it…

Do BMMFs, the novel infectious agents found in dairy products and bovine sera, play a role in the development of colorectal cancer? Scientists led by Harald zur Hausen detected the pathogens in colorectal cancer patients in close proximity to tumors. The researchers show that the BMMFs trigger local chronic inflammation, which can cause mutations via activated oxygen molecules and thus promote cancer development in the long term.

Women have an increased risk of breast cancer if they have a family history of this disease. However, the risk may also be higher if first-degree family members have another type of cancer, according to a study by a team of scientists and physicians from the National Center for Tumor Diseases (NCT) Heidelberg, the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD), as well as international colleagues.

Article - 10/03/2021

Faster to single cells using miniature grinder

Tissue cells are needed for medical diagnostics, cell therapies and tissue engineering, among other things. A novel tissue grinder gently and automatically dissociates cells from tissue. In November 2020, the newly founded biotech company Fast Forward Discoveries GmbH (FFX) delivered its first tissue grinders to customers.

Induced pluripotent stem cells (iPSC) are suitable for discovering the genes that underly complex and also rare genetic diseases. Scientists from the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL), together with international partners, have studied genotype-phenotype relationships in iPSCs using data from approximately one thousand donors.

So-called silent mutations have no effect on the composition of a protein. They are therefore not considered to promote cancer. However, scientists from the German Consortium for Translational Cancer Research (DKTK), partner site Essen, now describe in a case of kidney cancer an overlooked silent mutation with a major impact on prognosis.

Neuroblastoma can spread relentlessly or shrink spontaneously. Scientists from the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg and the National Center for Tumor Diseases (NCT) Heidelberg have shown that some malignant neuroblastomas employ a trick to avoid cell death: they use a special mechanism to lengthen the telomeres at the end of their chromosomes.

Certain anchor proteins inhibit a key metabolic driver that plays an important role in cancer and developmental brain disorders. Scientists from the German Cancer Research Center (DKFZ) and the University of Innsbruck, together with a Europe-wide research network, discovered this molecular mechanism, which could open up new opportunities for personalized therapies for cancer and neuronal diseases. They published their results in the journal Cell.

A specific variant of the surface protein VSG of African trypanosomes, the causative agents of sleeping sickness, is associated with resistance to the important drug Suramin. Scientists at the German Cancer Research Center have now been able to find a possible explanation for the formation of resistance based on the crystal structure of this protein variant.

Article - 14/01/2021

Newly discovered RNA as growth driver in liver cancer

Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

Development of the genomDE genome database - 04/12/2020

Whole genome sequencing for diagnosing rare diseases

Grouped together, rare diseases are by no means a rare phenomenon; however, they are rarely correctly diagnosed and rarely properly treated. In most cases, there is no effective medication available. Rare disease centres staffed by experts have been set up in many German cities to speed up the often long and painful search for the right diagnosis and treatment. Whole genome sequencing is a component of general healthcare, used to identify…

New method for analysing blood samples - 26/11/2020

Personalised therapy monitoring for malignant melanomas

Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…

Lab-on-a-chip - 11/11/2020

Microfluidic platform for the best possible cancer therapy

Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.

Intestinal peptide heals lung - 14/10/2020

Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia

If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

Organ failure due to fatty liver - 24/09/2020

HepaRegeniX develops an active substance for liver regeneration

When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure.

Microstructure Technology - 17/07/2020

An electronic nose for many applications

Sensory organs are sophisticated masterpieces of nature. That is why humans have often tried to copy them. Be it cameras or microphones - there are technical objects that have always been based on natural models such as the eye or the ear. For a long time, however, no artificial sense of smell has featured in the technical repertoire. Now researchers at the Karlsruhe Institute of Technology (KIT) have developed an electronic nose. It can…

Review article (new edition) - 08/07/2020

Immunology – at the forefront of medical progress

Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.

Affimed GmbH - 01/07/2020

"Innate cell engager" fighting against cancer

In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.

Vaccine development - 02/06/2020

CureVac as a pioneer of mRNA technology - what is behind the novel COVID-19 vaccine?

All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…

Translational oncology - 26/05/2020

Translation: driver of cancer medicine

The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field.

Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

Article - 04/02/2020

Medicine from the blue blood of marine snails

A “living pharmacy” crawls on the ocean floor off the coastline that stretches from Southern California to Mexico: biosyn Arzneimittel GmbH, a pharmaceutical company based in the city of Fellbach in southern Germany, produces a drug to treat bladder cancer, using the haemolymph, a vertebrate fluid equivalent to blood, of Megathura crenulata, commonly known as a giant keyhole limpet.